Related references
Note: Only part of the references are listed.The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
E. Alejandro Sweet-Cordero et al.
SCIENCE (2019)
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2
Liying Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE
N. Gaspar et al.
ANNALS OF ONCOLOGY (2018)
Precision medicine in pediatric oncology
Suzanne J. Forrest et al.
CURRENT OPINION IN PEDIATRICS (2018)
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E. Place et al.
FUTURE ONCOLOGY (2018)
Preliminary findings from part 1 of COMBI-i: A phase III study of anti-PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genome-scale CRI SPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Bjorn Stolte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Xiaotu Ma et al.
NATURE (2018)
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
Brittany C. Michel et al.
NATURE CELL BIOLOGY (2018)
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Gerard L. Brien et al.
ELIFE (2018)
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang et al.
CELL CHEMICAL BIOLOGY (2018)
Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents
Meredith K. Chuk et al.
CLINICAL CANCER RESEARCH (2017)
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Lori S. Hart et al.
CLINICAL CANCER RESEARCH (2017)
Precision medicine in pediatric oncology: Lessons learned and next steps
Rajen J. Mody et al.
PEDIATRIC BLOOD & CANCER (2017)
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study
Yael P. Mosse et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group
Lia Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Carl E. Allen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
From class waivers to precision medicine in paediatric oncology
Andrew D. J. Pearson et al.
LANCET ONCOLOGY (2017)
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective
Lucas Moreno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Carl E. Allen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Atezolizumab (A) plus cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
Wilson H. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pediatric oncology enters an era of precision medicine
Nita L. Seibel et al.
CURRENT PROBLEMS IN CANCER (2017)
Small-Molecule PROTACS: New Approaches to Protein Degradation
Momar Toure et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Equal access to innovative therapies and precision cancer care
Agnes Buzyn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors The Individualized Cancer Therapy (iCat) Study
Marian H. Harris et al.
JAMA ONCOLOGY (2016)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob et al.
LANCET ONCOLOGY (2015)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Scott C. Bresler et al.
CANCER CELL (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project
Mignon L. Loh et al.
BLOOD (2013)
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia
Guilherme Augusto dos Santos et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts et al.
CANCER CELL (2012)
Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors
R. Bagatell et al.
CLINICAL CANCER RESEARCH (2011)
A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in Phase I dose-finding studies
Alexia Iasonos et al.
CLINICAL TRIALS (2008)
Shortening the timeline of pediatric phase I trials: The rolling six design
Jeffrey M. Skolnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
